Overview

Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

The objective of the study is to evaluate the pharmacokinetics of vortioxetine and its metabolites in connection with multiple oral dosing in child and adolescent patients with a DSM-IV-TR diagnosis of Depressive or Anxiety Disorder

Phase:

Phase 2

Details

Lead Sponsor:

H. Lundbeck A/S

Treatments:

Vortioxetine